spleen volume reduction by 35% and total symptom score reductions of at least 50% at 24 weeks. It would be interesting to know what the numbers were say at 52 weeks, as we know our patient population continues to improve.
treatment-emergent adverse effects (TEAEs) included gastrointestinal (GI) events such as nausea (any grade, 42%; grade 3/4, 4%), diarrhea (41%; 6%), and vomiting (25%; 2%)
The side effects were mostly grade 1 and 2 and onset predicable, mostly seen from days 2-9.
They're moving into the phase 3 trial and moving it further up the patient population.
"This is going to be evaluating navtemadlin in the sub-optimal responders to see if we can move the drug even further up in its development pathway and benefit patients earlier on"
SNT Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)